为肝细胞癌武装 GPC3 CAR-T 细胞：多少才足够，下一步是什么？
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
肝细胞癌患者接受仑伐替尼与阿替利珠单抗联合贝伐珠单抗治疗后行肝切除术的瘤周区域 TIL（肿瘤浸润淋巴细胞）计数差异
英文原题：Differences in Tumor-Infiltrating Lymphocyte Counts in the Peritumoral Area in Patients Undergoing Hepatic Resection After Lenvatinib and Atezolizumab Plus Bevacizumab Therapy for Hepatocellular Carcinoma.
查看英文原题
Differences in Tumor-Infiltrating Lymphocyte Counts in the Peritumoral Area in Patients Undergoing Hepatic Resection After Lenvatinib and Atezolizumab Plus Bevacizumab Therapy for Hepatocellular Carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
在 ATZ/BEV 治疗后，瘤周区域的 TIL 计数，包括 CD3+ 和 CD8+ TILs，显著高于 LEN 治疗后。
中文摘要
目的
随着全身治疗进步，近年来可接受肝切除的肝细胞癌（HCC）患者增多，但尚无研究评估肿瘤周围区域的免疫状态。
方法
纳入14例接受仑伐替尼（LEN，7例）或阿替利珠单抗联合贝伐珠单抗（ATZ/BEV，5例）治疗后行肝切除的患者。通过苏木精-伊红染色和免疫组化评估肿瘤周围区域TIL（肿瘤浸润淋巴细胞），包括CD3+和CD8+ TIL。
结果
LEN和ATZ/BEV治疗后的TIL中位数分别为32和92个/0.237 mm²（P=.0044）；CD3+ TIL中位数分别为26和71个/0.237 mm²（P=.0057）；CD8+ TIL中位数分别为14和42个/0.237 mm²（P=.0044）。
结论
ATZ/BEV治疗后肿瘤周围区域的TIL（包括CD3+和CD8+ TIL）计数显著高于LEN治疗后。
展开英文摘要原文
METHODS
We enrolled 14 patients who underwent hepatic resection after lenvatinib (LEN, n = 7) or atezolizumab plus bevacizumab (ATZ/BEV, n = 5) therapy. Tumor-infiltrating lymphocytes (TILs), including CD3+ and CD8+ TILs, in the peritumoral area were evaluated by hematoxylin and eosin staining and immunohistochemistry.
RESULTS
The median TIL counts after LEN and ATZ/BEV therapy were 32 and 92 cells/0.237 mm 2 , respectively (p = 0.0044). The median CD3+ TIL counts after LEN and ATZ/BEV therapy were 26 and 71 cells/0.237 mm 2 , respectively (p = 0.0057). The median CD8+ TIL counts after LEN and ATZ/BEV therapy were 14 and 42 cells/0.237 mm 2 , respectively (p = 0.0044).
CONCLUSION
TIL counts, including those of CD3+ and CD8+ TILs, in the peritumoral area were significantly higher after ATZ/BEV than after LEN therapy.
论文信息
- 作者
- Toshida K、Itoh S、Tanaka Y、Toshima T、Yoshiya S、Izumi T、Iseda N、Tsutsui Y
- 单位
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.Japan
- 期刊
- Cancer medicine2025 Apr
- 原文标识
- PubMed 40249381 · DOI 10.1002/cam4.70445
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →